Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental pill for stomach paralysis shows promise in early trial

NCT ID NCT04026997

Symptom relief Sponsor: CinDome Pharma, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an oral drug called CIN-102 in 72 adults with gastroparesis (delayed stomach emptying) caused by diabetes or unknown reasons. Participants received one of three doses of CIN-102 or a placebo to see if it improved stomach emptying and reduced nausea. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CIN-102 (oral drug)
What this could lead to
If successful, CIN-102 could offer a new treatment option to improve stomach emptying and reduce nausea in people with gastroparesis.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. It is unclear if CIN-102 is effective or safe long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

72 people

The number who actually took part.

Started

Sep 2019

Finished

Dec 2020

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female patients 18 to 70 years old. * Current diagnosis of idiopathic or diabetic gastroparesis OR documented delayed gastric emptying. * Presence of moderate to severe nausea. * Body mass index (BMI) between 18 and 40 kg/m2, inclusive. * Glycosylated hemoglobin level \<11% at Screening. * Willing to washout from ongoing treatment for gastroparesis. * Able to understand and willing to comply with all study visits, procedures, restrictions, and provide written informed consent according to institutional and regulatory guidelines. Exclusion Criteria: * Other known disorder or treatment which could explain or contribute to symptoms of gastroparesis. * Positive test for drugs of abuse at the screening or evaluation visits. * Personal or family history of prolonged heart rate-corrected QT. * History or evidence of clinically significant arrhythmia. * History of gastrectomy, fundoplication, vagotomy, pyloroplasty, or bariatric surgery. * Females who are pregnant, nursing, or planning on becoming pregnant during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastroparesis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroparesis idiopathic gastroparesis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastroparesis

Contacts and locations

Locations

  • Research Site 101

    Chula Vista, California, 91910, United States

  • Research Site 102

    Boston, Massachusetts, 02215, United States

  • Research Site 103

    Louisville, Kentucky, 40202, United States

  • Research Site 104

    Monroe, Louisiana, 71201, United States

  • Research Site 105

    Tulsa, Oklahoma, 74104, United States

  • Research Site 106

    Philadelphia, Pennsylvania, 19140, United States

  • Research Site 107

    Jackson, Tennessee, 38305, United States

  • Research Site 109

    Great Neck, New York, 11023, United States

  • Research Site 110

    Kansas City, Kansas, 66045, United States

  • Research Site 111

    Atlanta, Georgia, 30322, United States

  • Research Site 112

    Marrero, Louisiana, 70072, United States

  • Research Site 113

    Las Vegas, Nevada, 89123, United States

  • Research Site 114

    Jacksonville, Florida, 32224, United States

  • Research Site 115

    Rapid City, South Dakota, 57702, United States

  • Research Site 117

    Miami, Florida, 33134, United States

  • Research Site 118

    Miami, Florida, 33183, United States

  • Research Site 119

    Summerville, South Carolina, 29485, United States

  • Research Site 120

    Winston-Salem, North Carolina, 27103, United States

  • Research Site 121

    Omaha, Nebraska, 68134, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.